NORD Launches New RFP for Patient Registries
Implementation of two new patient registries on the IAMRARE® platform funded by RDCA-DAP®
Funding is made available through the Rare Disease Cures Accelerator – Data and Analytics Platform (RDCA-DAP®), a collaborative agreement with the Critical Path Institute funded by the U.S. Food and Drug Administration (FDA).
Successful applicants will actively work with NORD, beginning in
Successful applicants will meet the following criteria:
- 501(c)(3) organization representing a community that meets the criteria for designation as a rare disease
- Priority consideration will be given to NORD Member Organizations
- Commitment and resources to begin registry work in
April 2026 and run a natural history study for a minimum of five years, including:- At least two staff members (paid or volunteer) with a combined minimum of 20 hours per week to dedicate to the registry
- A
U.S. -based Principal Investigator (PI) - Sufficient financial resources to support annual maintenance fees of approximately
$5,000 per year (this cost is estimated and may change based on levels of support)
- Commitment to the submission of data generated by the registry to the RDCA-DAP
- Support from rare disease community and experts who will be able to contribute to the design and success of the project, including selecting disease-specific questions and patient engagement and retention
How to Apply:
The application period opens on
About IAMRARE
®
The IAMRARE Platform hosts over 45 registries that are sponsored by patient advocacy organizations for the purpose of collecting patient reported data. For more information, visit https://rarediseases.org/iamrare-registry-program/.
About the National Organization for Rare Disorders
Founded in 1983, the National Organization for Rare Disorders (NORD®) is a leading independent, nonpartisan, nonprofit patient advocacy organization dedicated to improving the health and lives of over 30 million Americans living with rare diseases. In partnership with more than 350 disease-specific member patient organizations, NORD drives progress in rare disease research, care, and policy. Learn more at https://rarediseases.org/.
About RDCA-DAP
RDCA-DAP is an FDA-sponsored initiative that provides a centralized and standardized infrastructure to support and accelerate rare disease characterization with the goal of accelerating therapy development. For information, visit https://c-path.org/programs/rdca-dap/.
View original content to download multimedia:https://www.prnewswire.com/news-releases/nord-launches-new-rfp-for-patient-registries-302615783.html
SOURCE National Organization for Rare Disorders (NORD®)
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Largest law firm merger in history creates Hogan Lovells Cadwalader
- Dimensional Fund Advisors Ltd. : Form 8.3 - GAMMA COMMUNICATIONS PLC - Ordinary Shares
- Sands China Celebrates Sixth Consecutive Year in Dow Jones Best-in-Class Indices
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesRelated Entities
FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share